orders. We then focus on the mechanistic basis of microbial immunomodulation, which is presented using several wellunderstood paradigmatic examples, that is, helminths, Helicobacter pylori , Bifidobacteria and Lactobacilli. In a final chapter, we highlight past and ongoing attempts at harnessing the immunomodulatory properties of GI microbiota species and their secreted products for intervention studies and describe the promises and limitations of these experimental approaches. The effects of pro-and prebiotics, bacterial lysates, as well as of fecal microbiota transplantation are presented and compared. 
versity and alterations due to environmental influences [1] . They are based on the amplification and sequencing of parts of the 16S rRNA gene [1, 2] ; alternatively, metagenome or metatranscriptome sequencing is applied to obtain a higher resolution overview of the microbiota and to allow the detection of archaea, fungi, and viruses in addition to bacteria [1] [2] [3] . Other emerging methods are metaproteomic and metabolomic analyses, aiming to characterize the functionality of the microbiome [2, 3] . Through application of these modern culture-independent as well as culture-dependent methods, it has become increasingly clear that the composition of the gut microbiota is strongly influenced by environmental and lifestyle factors, which in turn affect the risk of allergic and other non-communicable diseases (NCDs). Better personal hygiene, smaller family size, dietary changes, and the excessive use of antibiotics in industrialized countries have all been held responsible for changes in the gut microbiota and allergy risk [4] [5] [6] . Several studies have reported beneficial effects on allergic outcomes of growing up in rural farming environments; livestock exposure, and therefore, early or prenatal microbial exposure appears to account for the lower allergy risk of farmers' children [7, 8] , which has been attributed mechanistically to differences in innate immune responses, as well as increased number and functions of cord blood regulatory T cells [9, 10] . Moreover, bacterial communities in dust samples isolated from households with dogs or cats were found to be richer and more diverse, and exposure to such environments during infancy is known to protect against allergic disease development in childhood [11, 12] .
A reduced GI tract microbiota diversity is clearly linked to early-onset NCDs, including atopy [13] , eczema [14] [15] [16] [17] , and asthma [18] . The reduced GI microbiota diversity in allergic children is dominated by Firmicutes [19] [20] [21] , and members of the Bacteroidaceae family [22] and more specifically, by increased numbers of Bacteroides fragilis [23, 24] , Escherichia coli [25] , Clostridium difficile [17, 25, 26] , Bifidobacterium catenulatum [19] [20] [21] 27] , and Bifidobacterium longum [28] [29] [30] , and a lower prevalence of Bifidobacterium adolescentis [28] [29] [30] , Bifidobacterium bifidum [28] [29] [30] , and Lactobacillus species [29] [30] [31] . These general trends are not confirmed by all studies; for instance, a study in Norway found a lower rather than higher concentration of E. coli among allergic individuals [28] . Also, in a study by Verhulst et al. [32] , children who developed wheezing had a lower prevalence of C. difficile . The reduced exposure of Western populations to microbes that are not classically categorized as constituents of the commensal microbiota, such as the gastric colonizer and pathobiont Helicobacter pylori [33] [34] [35] , or intestinal helminths [36, 37] , also increases the risk of allergic diseases.
Lifestyle factors such as delivery mode and breast-feeding strongly affect the establishment of the human gut microbiota and the risk of allergic outcomes. The recent finding that bacterial DNA is present in the newborn's first stool and in the fetoplacental unit suggests that the acquisition of the intestinal microbiota may already begin in utero and is then further shaped during birth and postnatally [38] [39] [40] . At birth, first major microbial exposures originate from the maternal vaginal and perianal microbiota. Consequently, the intestinal microbiota of newborns resembles that of his or her mother's vagina [41] . In contrast, neonates delivered by means of cesarean section (CS) acquire a gut microbiota that is similar to the one found on maternal skin. This is then followed by the typically slower (compared to vaginally delivered infants) acquisition of a more complex microbiota [42, 43] . Infants born by means of CS are at higher risk for respiratory distress [44] , asthma and atopy [45] , as well as obesity [46] , and type I diabetes [47] . Furthermore, CS involves antibiotic exposure and can delay the onset of breastfeeding, which negatively influence the establishment of a normal healthy gut microbiota [14, 48, 49] . Indeed, breastfed (>4 months) neonates exhibited a reduced risk of developing asthma until 8 years of age [50] . Evidence is available that breastfeeding protects against atopic dermatitis, wheeze in early childhood and cow's milk allergy [51] . However, the data are inconsistent, as other studies have reported no benefit of breastfeeding in children from nonatopic families or in decreasing the risk of asthma in infants at 5 years of age [52, 53] . Overall, the aforementioned studies imply that early-life or even prenatal exposure to microbes is critical for shaping a healthy GI tract microbiota, which can lower allergy risk later in life.
Mechanisms of Microbially Induced Immune Tolerance and Protection Against Allergic Disorders

Intestinal Helminths Protect against Allergy, IBD and Autoimmunity by Suppressing Innate Lymphoid Cell Activation and Promoting Treg Differentiation
Epidemiological and experimental studies have documented a clear inverse association between helminth infections and allergic, chronic inflammatory and autoimmune disease manifestations (reviewed in [54, 55] ). Parasites release immunomodulatory products that have evolved to suppress Th2-driven immunity and to ensure helminth persistence, and that, when administered to uninfected mice, reproduce many of the beneficial effects of live infection [56] . One of the most commonly used murine models of helminth infection takes advantage of the mouse intestinal nematode species Heligmosomoides polygyrus , which can be administered alive in larval form and which will colonize virtually all laboratory mouse strains, and of its excretory/secretory products ( H. polygyrus excretory/secretory antigen, helminth excretory/secretory (HES)). Experimental H. polygyrus infection triggers a Th2-predominant immune response that is accompanied by regulatory T-cell expansion and activation in the draining mesenteric lymph nodes (MLN) [57] and that typically fails to eliminate the parasites. Live nematode parasite infection of mice, as well as the adoptive transfer of MLN-derived Tregs from infected donors to uninfected recipients, suppresses allergen-induced airway hyper-responsiveness in the recipients and confers protection against allergy [58] ( fig. 1 ). The treatment of naive T-cells with HES in conjunction with a TCR ligand was shown to trigger the expression of the Treg lineagedefining transcription factor FoxP3 in vitro through the stimulation of TGF-β receptor II signaling, generating Tregs with suppressive activity in asthma models [59] . A 233 more recent report on Treg depletion in asthma models has, however, challenged the critical role of FoxP3 + Tregs in HES-induced asthma protection, instead implicating effects on innate lymphoid cells (ILCs) in allergen-specific immune suppression. This study found that the alumadjuvanted sensitization with ovalbumin, which constitutes the first phase of allergen-induced asthma in the widely used alum/ovalbumin-induced model of the disease, triggers the production of IL-5, IL-13 and other cytokines from type 2 ILCs, which is strongly suppressed by HES [60] ( fig. 1 ). Similar findings have been reported in an adjuvant-independent model of fungal extract-induced airway hyper-responsiveness [56] . In addition to Tregs and ILCs, dendritic cells (DCs) have been implicated in immunosuppression by both live parasites and HES. Treatment with HES inhibits DC-specific cytokine production upon TLR activation, as well as other DC functions [61] , a phenomenon that may be recapitulated in vivo by the expansion and tolerogenic Treg-inducing activity of CD11c lo DCs in the context of H. polygyrus infection [62] . In summary, many of the critical cellular and molecular players driving helminth-specific immunomodulation have been identified in the H. polygyrus mouse model; in contrast, comparatively little is known about the correlates of allergy protection by parasites in humans. Helminth-infected humans are known for their general T-cell hyporesponsiveness [63] , which in experimental studies on helminth (Ascaris, Trichuris)-infected children in Indonesia has been attributed to the higher suppressive activity of their FoxP3 + Tregs relative to those of uninfected children [64] . Other studies have documented higher frequencies of FoxP3 + Tregs in Schistosoma -infected children relative to their uninfected counterparts [65] . An additional, less well understood subset of regulatory lymphocytes, that is, regulatory B-cells (Bregs), has also been implicated in helminth-induced allergy protection in humans [66] . Adoptive transfer experiments have confirmed the protective activity of Bregs in models of allergen-induced asthma [66] . The CD24 hi CD27
+ subset of B-cells, through its capacity to secrete IL-10, appears to be specifically involved in helminthspecific immuno-suppression; both the frequency and functionality of this subset are reduced in allergic individuals [67] .
The Gastric Pathobiont H. pylori Suppresses Allergic Asthma and IBD by Promoting Tolerogenic DC and Regulatory T-Cell Responses
H. pylori is an ancestral constituent of the gastric microbiota that has colonized and co-evolved with its human host for at least 60,000 years [68] . H. pylori causes histologically evident, but mostly asymptomatic gastritis in all carriers, which may progress to more severe gastric disorders such as gastric and duodenal ulcers, and gastric cancer or B-cell lymphoma (recently reviewed in [69] ). Whether an infected individual will develop a clinically overt disease depends on the host genetic predisposition, virulence of the infecting strain, and the polarization and strength of the host immune response to the infection [70] . While T-cell responses of patients with H. pyloriassociated diseases, such as duodenal ulcer, are generally Th1/Th2-driven, T-cell responses in asymptomatic carriers tend to be Treg-predominant, with high levels of IL-10 and TGF-β production [71] . Similarly, children who rarely suffer from H. pylori -associated diseases despite being colonized at high levels, predominantly mount Treg responses to their strain [72] . Despite its strict host specificity ( H. pylori has not been isolated from any other mammalian species), certain isolates of H. pylori can be used for experimental infection of mice [73, 74] . The requirements for eliciting histologically evident gastric diseaseatrophic gastritis, intestinal metaplasia and other preneoplastic lesions -are similar in the human and murine host, with a specific contribution of the Cag pathogenicity island to premalignant transformation being observed in both settings [73, 75] . Experimental murine infection can be used to recapitulate both asymptomatic carriage and H. pylori -associated disease, with the outcome being driven by a single variable, that is, the age at the time of first exposure [73] . While mice infected during adulthood develop chronic gastritis and preneoplastic lesions over time, mice infected during the neonatal period will mimic the asymptomatic human carrier and be protected against gastric pathology [73] ( fig. 2 ). The neonatal infection model generates immune tolerance towards H. pylori that is driven by highly suppressive, CD4 + CD25 hi FoxP3 + Tregs, which suppress anti-H. pylori T-effector cell-mediated immunity [73] . An interesting side effect of neonatally induced immune tolerance is the efficient protection of infected mice against allergic asthma, which is evident in ovalbumin/alum-and house dust mite-induced asthma models [76, 77] . Experimental data reflect epidemiological studies in human populations, which have documented an inverse association of H. pylori infection with the risk of developing allergic asthma, atopic rhinitis and other allergic disease manifestations [78] [79] [80] [81] [82] . The inverse association of H. pylori status and allergy risk was particularly striking in children and earlyonset asthmatics, suggesting that young individuals benefit most from harboring H. pylori [78, 80, 81] . As in hel- Kyburz . 2 ) ; the depletion of Tregs breaks tolerance and abrogates protection, whereas the adoptive transfer of MLN-derived CD25 + Tregs is sufficient to protect naive recipients against allergic asthma [73, 76] . Several H. pylori factors are critical for Treg differentiation in the context of neonatal infection with the bacteria; in particular, the secreted factors γ-glutamyl-transpeptidase (GGT) and the vacuolating cytotoxin (VacA) both non-redundantly contribute to Treg differentiation, immune tolerance and asthma protection [83] ( fig. 2 ). Both are essential persistence factors in H. pylori infection [83] and expressed in all strains; both factors can further be administered in purified form to recapitulate all critical features of immune tolerance and allergy protection observed with live infection [84] . Treg differentiation upon exposure to VacA + GGT + H. pylori requires DCs, which are actively targeted and 'tolerized' by H. pylori via the two secreted factors [83] . H. pylori -experienced DCs retain a semi-mature phenotype, expressing high levels of MHCII, but low or no costimulatory molecules [83, 85] . Semi-mature DCs are tolerogenic, that is, they exhibit a high propensity for priming Treg differentiation, but have only a limited ability to prime effector T-cell responses [86, 87] . The tolerogenic DC/Treg axis likely accounts for the protection of H. pylori -infected individuals not only against allergic diseases but also against IBD [88] [89] [90] [91] ( fig. 2 ) and potentially against auto-immunity, as demonstrated in models of multiple sclerosis [92] . Overall, much can be learned about general microbial immune modulation by studying H. pylori due to readily available experimental infection models and the ease of genetic manipulation of these highly persistent colonizers of the human stomach.
Immunomodulatory Lactobacilli and Bifidobacteria Induce IL-10 and Retinoic Acid Expression in DCs and Promote Treg Differentiation
Given the large amount of interventional trials using various strains of Lactobacilli and Bifidobacteria (see chapter below), it is astonishing how little experimental information is available regarding the mechanistic basis underlying the protective effects of these classes of microbes on allergic and other immunologically driven diseases. However, a few concepts have emerged that apply to more than one strain and have been tested in rigorous experimental systems. One such model system utilizes Bifidobacterium infantis , a strain that was originally isolated from surgically removed, human intestinal mucosa and was shown to adhere closely to epithelial cells without inducing NF-κB activation and secretion of cytokines and chemokines [93] . Moreover, B. infantis co-culture not only fails to induce, but actively suppresses the release of pro-inflammatory molecules by epithelial cells exposed to live Salmonella spp. or purified TLR ligands; similar effects are observed with another immunomodulatory organism, Lactobacillus salivarius [93, 94] . A second, non-epithelial target cell of B. infantis is the antigen-presenting cell, especially the DC. Upon sampling antigenic material at sites of pathogen entry, such as the GI mucosa, immature sentinel DCs undergo maturation and migrate to the tissue-draining lymphoid organs, where they present pathogen-specific and co-stimulatory molecules (MHC peptide complexes and B7 family molecules) to naive T-helper cells. A third, soluble signal provided by the DC to the naive T-cells during antigen presentation determines the polarization of the T-cell into Th1, Th2, Th17 or Treg lineages; the nature of the third signal is governed by the conditions encountered by the DCs during antigen sampling. Interestingly, DCs directly cultured or derived from various human sources (MLN, blood) all consistently secrete IL-10, TGF-β and retinoic acid, but not IL-12 or TNF-α, upon co-culture with B. infantis [95, 96] . IL-10, TGF-β and retinoic acid all contribute to the differentiation of naive T-cells into Tregs rather than Th1 or other T-effector cells, a well-documented consequence of B. infantis administration to mice [96] . The CD103 + DC subset in the intestinal lamina propria is especially equipped to produce retinoic acid and promote Treg differentiation; high numbers of intestinal Tregs in turn drive the protection against colitis [96] and allergy that is a hallmark of Bifidobacteria ( B. infantis and other strains) feeding to mice [97] . Administration of B. infantis to human volunteers induced increased frequencies of FoxP3 + Tregs in peripheral blood [95] , lending further support to the notion that probiotic Bifidobacterium and Lactobacillus species alleviate allergic and chronic inflammatory diseases via the DC/IL-10/retinoic acid/Treg axis.
Interventional Trials Confirm Beneficial Effects of Probiotics on Allergic Disease Risk and Severity
In the past decades, a range of microbiota-derived products has been tested in human clinical trials of allergic and other immunological diseases. The applications can be divided into prebiotics, probiotics, bacterial lysates (BLs) and fecal microbiota transplantation (FMT). A majority of intervention studies have examined probiotic bacteria. Most studies monitor early outcomes of allergic diseases such as eczema and IgE-mediated food allergy, whereas only a few studies examine longer-term outcomes such as respiratory allergic disease.
Probiotics are live microorganisms which, when administered in adequate amounts, confer a health benefit to the host [98] . The first medical application of live bacteria was E. coli Nissle 1917 , which was isolated from a soldier who survived an epidemic of diarrhea during World War 1 [99] . The potential of live microorganisms was thereafter neglected for a long time in favor of pharmaceutical interventions. Most recent studies have been conducted using strains of Lactobacilli and Bifidobacteria, and they tend to show benefits in allergy prevention but not in the treatment of established allergies [38] . Several very recent trials published in 2013-2015, however, have raised new hopes that a reduction of symptoms in adult and pediatric allergic rhinitis, eczema and food allergy can be achieved by the use of probiotics ( table 1 ) . Systematic reviews and meta-analyses suggest that combined pre-and postnatal probiotic supplementation is most efficacious in preventing the development of infant eczema and atopic eczema [100] [101] [102] [103] , but no convincing data on beneficial effects on later-onset allergic diseases such as wheezing, allergic asthma or other allergic outcomes have been reported to date [104] [105] [106] [107] . The lack of efficacy in other allergic disorders may be attributable to the time point of treatment onset, which is often late in the last trimester of pregnancy or post-natally [108] ( table 1 ). Initiating interventions as early as the beginning of the second trimester has been found to increase efficacy [109] . Unconventional probiotics like Faecalibacterium prausnitzii , Akkermansia muciniphila , certain Clostridia or Bacteroides species may prove to be more promising than the predominantly used strains of Lactobacilli and Bifidobacteria in preventing allergic diseases [110] . The use of helminths has been propagated to treat allergies and inflammatory diseases, given the promising results from preclinical trials. However, helminths did not confer beneficial effects in allergic asthma patients, and outcomes for other atopic disorders in humans have been inconsistent [111] . BLs, that is, extracts from defined bacterial cultures, have originally been developed to prevent recurrent acute respiratory tract infections (ARTIs), including the common cold [112] . ARTIs are reported to exacerbate asthma and wheezing in childhood and to increase the risk of allergies later in life [113] . The best understood BL, OM-85 BV (also known as Bronchovaxom) consists of extracts of a mixture of bacterial pathogens causing respiratory tract infections [112] . Human clinical studies have revealed beneficial effects of OM-85 BV on the recurrence of ARTIs and a reduction of associated symptoms [113] [114] [115] [116] . Moreover, other BLs have been shown to reduce the recurrence and duration of ARTIs [117, 118] as well as a reduction of atopic dermatitis in infants at heredity risk for atopy [119] ( table 1 ) .
Motivated by promising experimental data in mice, several clinical trials have assessed the allergy-preventive effects of various non-digestible, fermentable oligosaccharides that are summarized under the term prebiotics. These diverse fibers promote the growth of endogenous gut bacterial species such as Bifidobacteria and Lactobacilli and thereby enhance microbial metabolic processes producing short chain fatty acids (SCFAs) with anti-inflammatory properties [120, 121] . A meta-analysis and systematic review of several studies found a significant reduction of eczema in infants and a reduction in asthma in infants at high risk of allergy upon prebiotic supplementation [122] . Recently, two trials could show decreased allergic food reactivity in young children after postnatal prebiotic application as well as alleviated clinical signs in infants with atopic dermatitis (see table 1 for most recent trials). However, due to the shortage of available data, the benefits of prebiotics on outcomes other than eczema remain to be examined [122, 123] .
FMT has attracted increased attention lately due to its great efficacy in the treatment of C. difficile -induced diarrhea. Several FMT trials for the treatment of IBD have recently been evaluated in a systematic review and meta-analysis. Overall, the remission rate was significantly increased, mainly for Crohn's disease (60.5%) and younger patients (7-20 years, 64.1%) and less convincingly for ulcerative colitis with a remission rate of only 22% [124, 125] . Moreover, FMT is currently being investigated as a therapy for pediatric allergic disorders [125] .
Conclusions and Future Perspectives
Observational, experimental and interventional studies all point to a critical role of a healthy and diverse GI tract microbiota in directing tolerance to harmless environmental or auto-antigens. Although experimental research and human trials have mostly focused on Lactobacilli and Bifidobacteria in the past, other, less well understood members of the microbiota may turn out to have stronger immunomodulatory effects and exhibit better efficacy in the prevention and treatment of allergic disorders. Among these are the gastric pathobiont H. pylori and intestinal helminths; both are persistent colonizers of their respective niche and share the ability to induce tolerogenic activity in DCs and Treg differentiation in naive T-cells. Longer interventional trials are needed to establish efficacy beyond atopic eczema in children, and to assess possible beneficial effects of pre-and postnatal treatment strategies on the allergy risk of adolescents and adults. The epigenetic basis for the intergenerational transmission of microbial immunomodulatory effects will receive increasing attention, and, in combination with global microbiome analyses at the genomic, transcriptomic and proteomic levels, will lead to a better understanding of the regulation of tolerance vs. allergy by the constituents of a healthy GI tract microbiota.
